Pan Q, Peppelenbosch MP, Janssen HL, Knegt RJ. Telaprevir/boceprevir era: From bench to bed and back. World J Gastroenterol 2012; 18(43): 6183-6188 [PMID: 23180937 DOI: 10.3748/wjg.v18.i43.6183]
Corresponding Author of This Article
Qiuwei Pan, PhD, Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Room L-462, ’s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. q.pan@erasmusmc.nl
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Field Of Vision
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Nov 21, 2012; 18(43): 6183-6188 Published online Nov 21, 2012. doi: 10.3748/wjg.v18.i43.6183
Telaprevir/boceprevir era: From bench to bed and back
Qiuwei Pan, Maikel P Peppelenbosch, Harry LA Janssen, Robert J de Knegt
Qiuwei Pan, Maikel P Peppelenbosch, Harry LA Janssen, Robert J de Knegt, Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, 3015 CE Rotterdam, The Netherlands
Author contributions: Pan Q contributed to conception, design, drafting the article and acquisition, interpretation of the data; Peppelenbosch MP, Janssen HLA and de Knegt RJ contributed to interpretation of data and editing the article; all the authors revised and approval of the version to be published.
Supported by Foundation for Liver and Gastrointestinal Research (SLO); and The Netherlands Organisation for Scientific Research (NWO), No. VENI-grant 916-13-032 (to Pan Q)
Correspondence to: Qiuwei Pan, PhD, Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Room L-462, ’s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. q.pan@erasmusmc.nl
Telephone: +31-10-7034545 Fax: +31-10-7032793
Received: August 6, 2012 Revised: September 25, 2012 Accepted: September 28, 2012 Published online: November 21, 2012
Abstract
Hepatitis C virus (HCV) infects approximately 200 million people worldwide. Interferon-based therapies have dominated over the past two decades. However, the overall response rates remain suboptimal. Thanks to the tremendous effort from both academia and industry, two serine protease inhibitors telaprevir and boceprevir for treating chronic hepatitis C have finally reached the clinic. Although these compounds are only approved for combination use with interferon and ribavirin in genotype 1 HCV infected chronic patients, the management of HCV patients however is now evolving incredibly. Here, we overviewed a series of landmark studies, regarding the clinical development of telaprevir and boceprevir. We discussed the mechanism-of-action of telaprevir/boceprevir and their potential application in HCV-positive liver transplantation patients. We further emphasized some emerging concerns with perspective of further development in this field.
